New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on November 18, 2025.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lilly Endowment Inc, a significant shareholder, has sold 9,886 shares of Eli Lilly & Co stock, amounting to a transaction value of $10,189,194.
Recent Updates on LLY stock
Recent developments for Eli Lilly & Co. (LLY) include updates on several clinical studies that could impact the company’s stock performance. Notably, the initiation of a Phase 2 study investigating brenipatide for smoking cessation highlights potential growth in a market with significant demand. Additionally, two Phase 3 studies involving baricitinib aim to address type 1 diabetes, which could enhance Eli Lilly’s position in the diabetes treatment market if successful. Furthermore, a Phase 4 study on the long-term safety of pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma, as well as a Phase 3 trial evaluating Vepugratinib for advanced bladder cancer, underscore Eli Lilly’s commitment to expanding its oncology portfolio. These studies, while in early stages, could positively influence investor sentiment and Eli Lilly’s competitive standing in the pharmaceutical industry.
Spark’s Take on LLY Stock
According to Spark, TipRanks’ AI Analyst, LLY is a Outperform.
Eli Lilly & Co’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The company’s robust revenue growth, market share gains, and strategic pipeline advancements are key strengths. However, high leverage, declining cash flow metrics, and a premium valuation present potential risks.
To see Spark’s full report on LLY stock, click here.
More about Eli Lilly & Co
YTD Price Performance: 33.33%
Average Trading Volume: 3,848,925
Technical Sentiment Signal: Buy
Current Market Cap: $969.3B